Zelluna / née Ultimovacs (ULTI) Fundamentale forhold

[Boms]

Det forventes vel å være like store sjanser som i Vikinglotto, men det er jo noen som vinner der og….

[TekBot]

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 8 May 2025 - Zelluna (OSE: ZLNA), a company pioneering allogeneic
‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the
treatment of cancer, announces its first quarter 2025 results today.
…

Vis børsmeldingen

Conference call and webcast scheduled for 8 May, 2025, at 09:00 (CET). Link to
webcast here
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20250508_7).

First Quarter 2025 Business Update

Highlights

• On 3 March 2025, Zelluna ASA announced the successful completion of a
  business combination between Ultimovacs ASA and Zelluna Immunotherapy AS, as
  well as a private placement resulting in gross proceeds of MNOK 51.7 at a
  subscription price of NOK 2.60 per Offer Share. These contemplated
  transactions were initially announced on 17 December 2024. All conditions
  for completion of the business combination were met, including confirmation
  by Euronext Oslo Børs that the requirements for the continued listing were
  met, as well as approval of the Prospectus and regulatory clearances. The
  name change from Ultimovacs ASA to Zelluna ASA was registered with the
  Norwegian Register of Business Enterprises, and the ticker code of the
  Company was changed from “ULTI” to “ZLNA”.
• On 22 April 2025, Zelluna reported that it has successfully developed,
  scaled and automated its proprietary manufacturing process for its TCR-NK
  cell therapies. This milestone represents a major advancement in the
  Company’s preparation for clinical entry to provide life-changing,
  innovative treatments for patients battling cancer. The proprietary
  manufacturing process is applicable to any product emerging from the
  Company’s pipeline which means any TCR-NK product can be plugged into the
  established manufacturing process strengthening Zelluna’s dominance of the
  TCR-NK therapeutic field. Based on the established manufacturing process,
  hundreds of doses could be produced from a single manufacturing batch
  highlighting scalability and low cost of goods potential.

Financial update

• Total operating expenses amounted to MNOK 22.2 in Q1 2025.
• Net negative cash flow from operations was MNOK 36.0 in Q1 2025. Proceeds
  from issuance of equity was MNOK 51.7, and net cash acquired in the business
  combination was MNOK 92.3, resulting in a net increase in cash and cash
  equivalents, not including currency effects, of MNOK 108.0 during Q1 2025.
  Cash and cash equivalents amounted to MNOK 135.3 as per March 31, 2025.
• A reverse share split was executed on 31 March 2025 and registered in the
  Norwegian Register of Business Enterprises. In the reverse split, 10 shares
  became 1 share, thus the new number of outstanding shares in the Company is
  20,227,066, each with a par value of NOK 1. In relation to the reverse share
  split, a share issue of 7 shares was necessary for the total number of
  shares to be divided by 10.

The quarterly report and presentation will be published at 07:00 CET on 8 May,
2025, and will be publicly available on the Zelluna website. The Company will
conduct a conference call and webcast at 09:00 CET the same day. Questions can
be submitted throughout the event. The webcast will be archived for replay
following the conference call. Link to webcast here
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20250508_7).

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
(https://www.globenewswire.com/Tracker?data=Z8lLmV-
B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup
zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
(https://www.globenewswire.com/Tracker?data=xw_BegYpiBk6hexlBFgOsk7tj2DC2GZ9wD-
xUL0RvSOAFKyBsXJCyN1-
yeYF_y4PiN7qNCFrqSFIFzf4Oy78pFiEzLGlsgS23tV0HELOjUoSe5eLjAVVxGWn_gS6AJdD)
Phone: +47 482 48632

About Zelluna ASA

Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through clinical development of TCR and cell-based
therapies including marketed products.

For more information, please visit www.zelluna.com
(https://www.globenewswire.com/Tracker?data=6siez1OIaoPCwM84VGFsI73ZbH54BnDSBKFm
vna_tY11PFEH7Ff3r6Kak3xnzzVSpOZx3-1OxY3u9bMPDFcz_sitG5kmja3-
vy_XZLcFNuhCpjQMdyWILy_Fma6seMkp553_d3ywUZGF-
pvjfJRH5PlneMcMycPZgYmXR3qT5IbtFGFLXa1y0ZFJFCfQPZvnlw5PswLpdCO0Mc6mZ02p6yeLVR7Pm
AVKrN8VFS1xFnfupxUalnqTrCzF5xMrGpjo_eyPbtIney8rlU9VYTgysHXRRoBtn-
DVON6NOVB_5xFexH9rRBVetaGoT0XLB9Q-
AOf1lNTaePkqVtz8BiFwrmhu4ZDWDuBVyhqIHG5CeinnlGXPact99W_OL1GRo30Q4-
KhQ6SbmRnm_jOBoZjFlDhBgv9nlp7I5poA0LJ7wMU9dbRko8dwtpJoWUCpAq58KHWnEIoMG1kN1NlPLk
6DVb_P4f1WrRpOS9rmXKXIK9EQw_3rPj5GDgYLLk6SVncTQN18GHaMOJ4eVGMi_H4WoU6s22jT7xghXH
FjmwiYBKmzX2MBaFOHT1ZKCcNpbPheZqGepyuUOOaFVPMv4RbTBI5GW3WEMRejVEHdS7by9EHOcDws4v
JX6Qrfyt5BipFK)

This stock exchange announcement was published by Joachim Midttun, Financial
Manager at Zelluna ASA, on 8 May, 2025 at 07:00 CET.

Kilde

[Boms]

Anbefaler de som ikke kjenner til Zelluna fra før å se på Webcasten og hør på hva CEO sier om potensialet og hvor viktig milepælen med at produksjonsmetoden nå er på plass.

[Has]

Dersom/når effekten dokumenteres vil potensialet utvilsomt være eventyrlig.

Multiklick og de gjenstående forsøkene med UV1 får lite plass i presentasjonen. Her kan resultater foreligge i nær framtid.

Kan det være en viss mulighet for at noe her kan sjokkere markedet?

[BalleKlorin]

Det kom også nylig ut en episode om Zelluna i Beyond Biotech podcast fra Labiotech:

TCR-NK: A novel cell therapy transforming cancer treatment - Beyond Biotech -...

Veldig nyttig å bli litt kjent med selskapets TCR-NK teknologi

[Boms]

Synes CEO har blitt mye bedre til å presentere selskapet. Også glad for å høre at de parallelt søker godkjennelse for kliniske forsøk i EU og USA.
USA med den nye ledelsen av FDA der kan man ikke stole på, det er mye følelser, konspi og kjepphester til at man kan være sikker på tidslinjer og hva som skal til for å få godkjennelser.

[Has]

Planen er å komme i gang med kliniske forsøk allerede i år, og første resultater ventes neste år.

Det stilles krav til resultater fra prekliniske utprøvinger for å få godkjenning for å gå videre med kliniske forsøk.

Er det vanlig å presentere resultatene fra de prekliniske utprøvingene?

[Boms]

Hvor viktig det er kan vel sikkert diskuteres, men litt artig at selskapet legges merke til utenfor Norge med en nominasjon til European Mediscience Awards 2025:

Nominations overview

[Boms]

Ny episode av Radium med Namir Hassan fra Zelluna som gjest. Har ikke hørt igjennom selv ennå. Men høres ut som en grundig gjennomgang.
https://soundcloud.com/user-972208711/episode-330

[Has]

Her er det fullt fokus på Zellunas plattform.

Avlesning av Dovacc i samarbeid med Astra Zeneca er like om hjørnet. Kan her komme overraskelser?

[TekBot]

ZLNA - Issuance of shares through set-off of option exercise fee

Oslo, 24 May 2025: Zelluna ASA (the “Company”) refers to the resolution by the
Company’s Annual General Meeting held on 29 April 2025 to grant the Company’s
Board of Directors an authorisation to issue new shares, each with a
…

Vis børsmeldingen

subscription price of NOK 26, to settle an amount of EUR 500,000 of an already
triggered option exercise fee towards Inven2. The Company’s Board of Directors
has today resolved to issue 227,096 new shares in the Company to Inven2 against
set-off of such amount of EUR 500,000.

After the share capital increase related to the issuance of the new shares has
been registered with the Norwegian Register of Business Enterprises, the Company
will have a share capital of NOK 20,454,162, divided into 20,454,162 shares,
each with a par value of NOK 1.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

Kilde

[TekBot]

ZLNA - New registered share capital

Oslo, 27 May 2025: Zelluna ASA (the “Company”) refers to the announcement on 24
May 2025 regarding a resolution by the Company’s Board of Directors to issue
227,096 new shares in the Company against set-off of an option exercise fee.
…

Vis børsmeldingen

The share capital increase related to the issuance of the new shares has now
been registered with the Norwegian Register of Business Enterprises, and the
Company’s new registered share capital is NOK 20,454,162, divided into
20,454,162 shares, each with a par value of NOK 1.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

Kilde

[TekBot]

Disclosure of Shareholding - Gjelsten Holding AS

Issuer: Zelluna ASA
ISIN: NO0013524942
Date of event triggering the notification: 27 May 2025
…

Vis børsmeldingen

Threshold crossed: 5%

In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten
Holding AS (“Gjelsten”) hereby notifies that its ownership interest in Zelluna
ASA (“Zelluna”) has fallen below the 5% threshold. Following a share capital
increase in Zelluna through a private placement registered in VPS on 27 May
2025, Gjelsten’s ownership has changed as follows:

• Previous shareholding: 5.02% of the share capital
• New shareholding: 4.96% of the share capital
• Total number of shares held: 1,014,972 shares

The reduction in ownership is due to dilution as a result of the private
placement. Gjelsten has not sold any shares.

This notification is submitted pursuant to Section 4-3 of the Norwegian
Securities Trading Act and the Oslo Rule Book II - Issuer Rules.

Kilde

[TekBot]

Disclosure of share transfer from Inven2 AS

Issuer: Zelluna ASA
ISIN: NO0013524942
Date of transaction: 25 June 2025
…

Vis børsmeldingen

Inven2 AS, a major shareholder in Zelluna ASA, has transferred a total of
120,796 shares in Zelluna ASA to two inventors, in accordance with a pre-
existing private agreement.

Following the transaction, Inven2 AS holds 2,207,033 shares in Zelluna ASA,
corresponding to 10.79% of the company’s outstanding shares.

Non-Regulatory Press Release

Kilde

[Has]

Nordnet

Forskningsleder Else Marit Inderberg med sitt selskap Wiarom inn med stor post på aksjonærlista.

[theroger]

Hun og Sébastien Wälchli som fikk overført aksjer fra Inven2

[Has]

Resultater av 2 siste studier om hjørnet?

[Has]

I følge årsrapporten var avlesning av 2 siste studier på UV1 forventet 1H 2025.

Dette ble i q1 rapporten korrigert til " i løpet av 2025."

Noen som tør å spekulere i grunnen til “forsinkelsen”?

[AndyO]

Lol, det er et svært sensitivt tema. Med en kostbar historikk.

[TekBot]

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29
April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’,
OSE ticker “ZLNA”) to grant new shares to employees and board members under a
…

Vis børsmeldingen

long-term incentive program, the Board of Directors has resolved to issue share
options to all employees in the Company.

A total of 1,634,000 options for shares in the Company have been distributed
amongst the employees and two board members. The number of options granted
corresponds to 8.0% of the outstanding number of shares in the Company. The
combined number of options granted under both the previous and current share
option programs corresponds to 8.7% of the outstanding shares.

Each option gives the right to acquire one share in the Company. The options are
granted without consideration. Pursuant to the vesting schedule for employees,
33% of the options will vest one year after the day of grant, 33% of the options
will vest two years after the day of grant and the remaining 33% will vest three
years after the day of grant (vesting is dependent on the option holder still
being employed in the Company). For the board members, all options vest after 1
year.

The exercise price has been set at NOK 13.34 per share, which corresponds to the
volume-weighted average price over the past 30 calendar days. Options that are
not exercised within 7 years from the date of grant will lapse and become void.

Primary insiders in Zelluna ASA have received the following option grants, on
the terms described above:

Chief Executive Officer, Namir Hassan, has been granted 550,000 share options.

Chief Financial Officer, Hans Vassgård Eid, has been granted 175,000 share
options. All 23,398 options under the previous program have been terminated.

Chief Operating Officer, Anders Holm, has been granted 145,000 share options.

Head of Research, Luise Weigand, has been granted 145,000 share options.

Head of CMC, Emilie Gauthy, has been granted 80,000 share options.

Head of Clinical Operations, Øivind Foss, has been granted 70,000 share options.
All 11,398 options under the previous program have been terminated.

Head of Project Management, Julia Ino, has been granted 80,000 share options.

Board Member, Bent Jakobsen, has been granted 96,000 share options.

Board Member, Eva-Lotta Allan, has been granted 6,000 share options.

For further information, please see www.zelluna.com (http://www.zelluna.com) or
contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
(https://www.globenewswire.com/Tracker?data=Z8lLmV-
B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup
zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
(https://www.globenewswire.com/Tracker?data=xw_BegYpiBk6hexlBFgOsk7tj2DC2GZ9wD-
xUL0RvSOAFKyBsXJCyN1-
yeYF_y4PiN7qNCFrqSFIFzf4Oy78pFiEzLGlsgS23tV0HELOjUoSe5eLjAVVxGWn_gS6AJdD)
Phone: +47 482 48632

Kilde